Diamond Home Page
  • Diamond Home Page
  • About Us
  • For Users
  • Industry
  • Public
  • Science
  • Instruments
  • Careers
  • More
Search

On this website

About Diamond

  • About Diamond
  • About Synchrotron
  • News and Features
  • Events
  • Contact Us
  • FAQ

For Users

  • Apply for beamtime
  • User guide
  • Diamond Users Commitee
  • FAQ

Industry

  • Techniques Available
  • Industry Research
  • Industry Case Studies
  • News
  • Meet the Industry Team

Science

  • Research
  • Computing
  • The Machine
  • Publications
  • Research Expertise
  • Membrane Protein Laboratory
  • Additional Facilities

Instruments

  • All the Instruments
  • Macromolecular Crystallography
  • Soft Condensed Matter
  • Imaging and Microscopy
  • Biological Cryo-Imaging
  • Magnetic Materials
  • Structures and Surfaces
  • Crystallography
  • Spectroscopy

Careers

  • Vacancies
  • Info for applicants
  • Company Benefits
  • Apprenticeships
  • PhD Studentships
  • Work Placement

Public

  • News
  • How Diamond Works
  • Multimedia
  • Features
  • Visits Us
  • For School

Procurement

  • Non-OJEU Tender Notices
  • OJEU PINs
  • OJEU Tender Notices
  • Registration Form

Software & Tools

  • Publications Database
  • iSpyB
  • User Administration System

Main Content

A brighter light for science
Sub-navigation
  • About Us
  • Governance
  • Legal & Compliance
  • News & Literature
  • Events
  • Contact Us
  • Location

In This Section

Sub Navigation
  • Latest News

Opportunities at Diamond

Learn more about career and student opportunities at Diamond:

Vacancies

Students

Diamond-II: Advancing Science

Find out more about our ambitious upgrade project, delivering more brightness, more coherence, and greater speed of analysis to UK science. More about Diamond-II

Diamond-II Logo

Coronavirus Science

Find out more about Diamond's response to virus research. 

COVID

  1. Diamond Light Source
  2. News & Features
  3. Latest News
  4. 2018 News
  5. Targeting Ebola

Targeting Ebola

Recent work at Diamond has helped to fuel the search for an Ebola vaccine.  Researchers expertly solved the crystal structures of drugs bound to the outer coating of the Ebola virus to pinpoint the regions that are essential for inhibitory activity.

Ebola is a viral disease that is highly infectious and associated with a high risk of death. It first arose in 1976, from which point it was associated with dozens of small-scale outbreaks; however, in 2013 Ebola was responsible for a huge epidemic in West Africa. Emergency was declared and over 11,000 people lost their lives to the virus. Despite this horrific state of affairs, Ebola still remains an untreatable disease and there is no vaccine to prevent infection.

   Tweet   

Determined to hamper future Ebola outbreaks, a team of researchers set out to explore the outer coating of the virus to see how it could be targeted by drugs. They were drawn to a substance known as a glycoprotein (a mixture of a sugar and a protein), which is responsible for binding to the host cell’s membrane to allow the infection to take hold.

Because of the recent global threat of Ebola, efforts were undertaken by many scientists to screen well-known drugs against the virus. Amazingly, these tests showed that common drugs that are used to treat other conditions (such as cancer, depression, heart disease and Parkinson’s) could directly interact with the Ebola glycoprotein.

Armed with this knowledge, the team of researchers used the macromolecular X-ray crystallography beamlines (MX), I02 and I24, at Diamond to uncover how these drugs interacted with the viral glycoprotein. They focussed on four drugs: benztropine, bepridil, paroxetine and sertraline, which they noted could all bind to the same large cavity within the glycoprotein. Importantly, the crystal structures showed that the exact binding position within the cavity and the regions that they interacted with varied hugely between the drugs. By analysing the structure of these drug complexes and correlating them with viral activity, the regions of the glycoprotein that are essential for activity could be determined.  

With this information it is hoped that potent Ebola inhibitors could be designed in the future so that we will not see a repeat of the recent costly epidemic. 

Related publication:

J Ren et al. Target identification and mode of action of four chemically divergent drugs against Ebola virus infection. Journal of Medicinal Chemsitry, 2017, DOI: 10.1021/acs.jmedchem.7b01249.

  • Contact Us
  • About Diamond Light Source
  • Careers
  • Procurement
  • Legal notices & Cookie policy
  • Supply Chain Transparency

Diamond Light Source

Diamond Light Source is the UK's national synchrotron science facility, located at the Harwell Science and Innovation Campus in Oxfordshire.

Copyright © 2022 Diamond Light Source

 

Diamond Light Source Ltd
Diamond House
Harwell Science & Innovation Campus
Didcot
Oxfordshire
OX11 0DE

See on Google Maps

Diamond Light Source® and the Diamond logo are registered trademarks of Diamond Light Source Ltd

Registered in England and Wales at Diamond House, Harwell Science and Innovation Campus, Didcot, Oxfordshire, OX11 0DE, United Kingdom. Company number: 4375679. VAT number: 287 461 957. Economic Operators Registration and Identification (EORI) number: GB287461957003.

feedback